Loading…
FLIXOTIDE ACCUHALER is a brand name for Fluticasone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Fluticasone propionate given by inhalation offers preventative treatment for asthma. At recommended doses it has a potent glucocorticoid anti-inflammatory action within the lungs, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Adults:…
Verbatim from this product's MHRA label. Tap a section to expand.
Patients should be made aware of the prophylactic nature of therapy with inhaled fluticasone propionate and that it should be taken regularly even when they are asymptomatic. If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.
Flixotide Accuhaler is for oral inhalation use only. Flixotide Accuhaler is suitable for many patients, including those who cannot use a metered-dose inhaler successfully. The dose may be increased until control is achieved or reduced to the minimum effective dose, according to the individual response.
The onset of therapeutic effect is within 4 to 7 days. Adults and children over 16 years: 100 to 1,000 micrograms twice daily. Prescribers should be aware that fluticasone propionate is as effective as other inhaled steroids approximately at half the microgram daily dose.
For example, a 100mcg of fluticasone propionate is approximately equivalent to 200mcg dose of beclometasone dipropionate (CFC containing) or budesonide. Due to the risk of systemic effects, doses above 500 micrograms twice daily should be prescribed only for adult patients with severe asthma where additional clinical benefit is expected, demonstrated by either an improvement in pulmonary function and/or symptom control, or by a reduction in oral corticosteroid therapy (see
). Patients should be given a starting dose of inhaled fluticasone propionate which is appropriate to the severity of their disease.
Typical Adult Starting Doses:
For patients with mild asthma, a typical starting dose is 100 micrograms twice daily. In moderate and more severe asthma, starting doses may need to be 250 to 500 micrograms twice daily. Where additional clinical benefit is expected, doses of up to 1000 micrograms twice daily may be used.
Initiation of such doses should be prescribed only by a specialist in the management of asthma (such as a consultant physician or general practitioner with appropriate experience). The dose should be titrated down to the lowest dose at which effective control of asthma is maintained.
Flixotide Accuhaler 250 micrograms is not suitable for use in children. The maximum licensed dose in children is 200 micrograms twice daily.
Special patient groups:
There is no need to adjust the dose in elderly patients or in those with hepatic or renal impairment. 1 (including lactose, which contains small amounts of milk-protein). 4 Special warnings and precautions for use The management of asthma should follow a stepwise programme, and patient response should be monitored clinically and by lung function tests.
Flixotide Accuhaler is not designed to relieve acute symptoms for which an inhaled short acting bronchodilator is required. Patients should be advised to have such rescue medication available. Sudden and progressive deterioration in asthma control is potentially life- threatening and consideration should be given to increasing corticosteroid dosage.
In patients considered at risk, daily peak flow monitoring may be instituted. Fluticasone propionate is not for use in acute asthma attacks, but for routine long-term management. Patients will require a fast- and short-acting inhaled bronchodilator to relieve acute asthmatic symptoms.
8 Undesirable Effects). Patients should be given a starting dose of inhaled fluticasone propionate which is appropriate to the severity of their disease.
Typical Adult Starting Doses:
For patients with mild asthma, a typical starting dose is 100 micrograms twice daily. In moderate and more severe asthma, starting doses may need to be 250 to 500 micrograms twice daily. Where additional clinical benefit is expected, doses of up to 1000 micrograms twice daily may be used.
Initiation of such doses should be prescribed only by a specialist in the management of asthma (such as a consultant physician or general practitioner with appropriate experience). The dose should be titrated down to the lowest dose at which effective control of asthma is maintained.
Flixotide Accuhaler 250 micrograms is not suitable for use in children. The maximum licensed dose in children is 200 micrograms twice daily.
Special patient groups:
There is no need to adjust the dose in elderly patients or in those with hepatic or renal impairment. 1 (including lactose, which contains small amounts of milk-protein). 4 Special warnings and precautions for use The management of asthma should follow a stepwise programme, and patient response should be monitored clinically and by lung function tests.
Flixotide Accuhaler is not designed to relieve acute symptoms for which an inhaled short acting bronchodilator is required. Patients should be advised to have such rescue medication available. Sudden and progressive deterioration in asthma control is potentially life- threatening and consideration should be given to increasing corticosteroid dosage.
In patients considered at risk, daily peak flow monitoring may be instituted. Fluticasone propionate is not for use in acute asthma attacks, but for routine long-term management. Patients will require a fast- and short-acting inhaled bronchodilator to relieve acute asthmatic symptoms.
1 (including lactose, which contains small amounts of milk-protein).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Fluticasone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Increasing use of short-acting inhaled β2-agonists to relieve symptoms indicates deterioration of asthma control.
If patients find that short-acting relief bronchodilator treatment becomes less effective, or they need more inhalations than usual, medical attention must be sought. g. higher doses of inhaled corticosteroids or a course of oral corticosteroids).
Severe exacerbations of asthma must be treated in the normal way. 8). This should be considered in particular when prescribing to patients with a history of diabetes mellitus. As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.
Flixotide Accuhaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods.
These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
It is important therefore that the dose of inhaled corticosteroid is reviewed regularly and reduced to the lowest dose at which effective control of asthma is maintained. Certain individuals can show greater susceptibility to the effects of inhaled corticosteroid than do most patients.
Because of the possibility of impaired adrenal response, patients transferring from oral steroid therapy to inhaled fluticasone propionate therapy should be treated with special care, and adrenocortical function regularly monitored.
Prolonged treatment with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis. Children aged < 16 years taking higher than licensed doses of fluticasone (typically ≥1000mcg/day) may be at particular risk.
Situations, which could potentially trigger acute adrenal crisis, include trauma, surgery, infection or any rapid reduction in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, hypoglycaemia, and seizures.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored.
If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
When changing from a dry powder inhaler to a metered dose inhaler, administration of high doses, above 1000 mcg daily, is recommended through a spacer to reduce side effects in the mouth and throat. However, this may increase drug delivery to the lungs.
As systemic absorption is largely through the lungs, there may be an increase in the risk of systemic adverse effects. A lower dose may be required. The benefits of inhaled fluticasone propionate should minimise the need for oral steroids.
However, patients transferred from oral steroids, remain at risk of impaired adrenal reserve for a […]
Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Increasing use of short-acting inhaled β2-agonists to relieve symptoms indicates deterioration of asthma control.
If patients find that short-acting relief bronchodilator treatment becomes less effective, or they need more inhalations than usual, medical attention must be sought. g. higher doses of inhaled corticosteroids or a course of oral corticosteroids).
Severe exacerbations of asthma must be treated in the normal way. 8). This should be considered in particular when prescribing to patients with a history of diabetes mellitus. As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.
Flixotide Accuhaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods.
These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
It is important therefore that the dose of inhaled corticosteroid is reviewed regularly and reduced to the lowest dose at which effective control of asthma is maintained. Certain individuals can show greater susceptibility to the effects of inhaled corticosteroid than do most patients.
Because of the possibility of impaired adrenal response, patients transferring from oral steroid therapy to inhaled fluticasone propionate therapy should be treated with special care, and adrenocortical function regularly monitored.
Prolonged treatment with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis. Children aged < 16 years taking higher than licensed doses of fluticasone (typically ≥1000mcg/day) may be at particular risk.
Situations, which could potentially trigger acute adrenal crisis, include trauma, surgery, infection or any rapid reduction in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, hypoglycaemia, and seizures.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored.
If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
When changing from a dry powder inhaler to a metered dose inhaler, administration of high doses, above 1000 mcg daily, is recommended through a spacer to reduce side effects in the mouth and throat. However, this may increase drug delivery to the lungs.
As systemic absorption is largely through the lungs, there may be an increase in the risk of systemic adverse effects. A lower dose may be required. The benefits of inhaled fluticasone propionate should minimise the need for oral steroids.
However, patients transferred from oral steroids, remain at risk of impaired […]